Selpercatinib and pralsetinib were approved in 2020 for patients with metastatic RET fusion-positive NSCLC, advanced or metastatic RET-altered MTC and papillary thyroid carcinoma. This evidence concerns the gene RET and thyroid gland papillary carcinoma.